Cepravin Dry Cow Intramammary Suspension

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Cefalonium dihydrate

Available from:

Intervet Ireland Limited

ATC code:

QJ51DA90

INN (International Name):

Cefalonium dihydrate

Dosage:

250 mg/syringe

Pharmaceutical form:

Intramammary suspension

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Cattle

Therapeutic area:

ZZZ Cefalonium

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

1988-10-01

Summary of Product characteristics

Health Products Regulatory Authority
22 February 2021
CRN00C62W
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cepravin Dry Cow Intramammary Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 3g syringe contains:
​
ACTIVE SUBSTANCE
​
​
Cefalonium
​250 mg
​
(as cefalonium dihydrate)
​
​
EXCIPIENTS
​
​
Liquid paraffin
to 3000 mg​
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Intramammary Suspension.
An off-white to buff-coloured intramammary suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
CEPRAVIN DRY COW is recommended for routine dry cow therapy to treat
existing sub-clinical infections and to prevent new
infections which occur during the dry period.
4.3 CONTRAINDICATIONS
Do not use in the lactating cow.
Not intended for use within 54 days of calving.
Do not use in animals with known hypersensitivity to penicillins or
cephalosporins.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS

Do not bend the nozzle.

Do not contaminate the nozzle

If calving occurs before 54 days after treatment, the absence of
antibiotic should be confirmed by testing before
the milk is used for human consumption. Milk for human consumption may
be taken after 54 days plus 96 hours
after treatment.

In cows suffering from hypocalcaemia it may be necessary to discard
milk for a longer period.

If the product is used in heifers during their first pregnancy the
same precautions should be observed as in cows,
i.e. infusions should be given not less than 54 days before calving
and milk discarded for the statutory four days
after calving.

Summer Mastitis - It is unlikely that antibiotic treatment alone will
control Summer Mastitis and therefore other
Health Products Regulatory Authority
22 February 2021
CRN00C62W
Page 2 of 5
measures should be implemented as part of routine management. The